Ratings
0
Nobody has rated this yet. Be the first!
The heterogeneity of human antibody responses to vaccinia virus revealed through use of focused protein arrays
Phase I Trial of Intravenous Oncolytic Vaccinia Virus (GL-ONC1) with Cisplatin and Radiotherapy in Patients with Locoregionally Advanced Head and Neck Carcinoma
Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses